on JTC Team, LLC (NASDAQ:VLON)
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in JTC Team's Virtual Investor Segment
Frenchtown, NJ / ACCESSWIRE / July 24, 2024 / JTC Team, a corporate communications and investor relations firm, released a Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics, Inc. (Nasdaq: SONN). Sonnet is a clinical-stage company focused on developing targeted immunotherapeutic drugs.
The segment includes discussions by Pankaj Mohan, PhD (Founder and CEO), Richard Kenney, M.D. (Chief Medical Officer), and Dr. Gael Hedou (Chief Operating Officer) of Sonnet BioTherapeutics. They highlighted the recent positive data from the company’s ongoing Phase 1b/2a clinical trial of SON-080, a drug aimed at treating chemotherapy-induced Peripheral Neuropathy (CIPN).
The Virtual Investor "What This Means" segment is available for viewing online. More segments from the series can be accessed on demand at www.virtualinvestorco.com.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all JTC Team, LLC news